EBR Systems Reports Strong Q4 Commercial & Clinical Progress, Preliminary FY25 Revenue
EBRCZ has more than doubled off its 52-week low of $0.321 on light trading volume (0.3× avg).
Summary
EBR Systems reported strong Q4 2025 commercial momentum with doubling implant volumes and initiated two key clinical studies, including one that could significantly expand its market.
Key Events · Product Development and Regulatory · EBRCZ
-
Doubling of WiSE System Implants
Commercial implant case volumes for the WiSE System doubled in Q4 2025 compared to Q3, with 18 implants during the quarter and 30 total for the pilot and Limited Market Release phases.
-
Preliminary Financial Results
The company expects preliminary unaudited Q4 2025 revenue between US$870K and US$935K, and total 2025 revenue between US$1,552K and US$1,617K.
-
Expansion of Commercial Reach
An additional 9 purchase agreements were signed, and 11 new physicians were trained, expanding the adoption of the WiSE System.
-
Commencement of WiSE-UP Study
The WiSE-UP post-approval study, designed to evaluate real-world outcomes for heart failure patients receiving the FDA-approved WiSE System, commenced with initial patient enrolments.
Analysis · EBRCZ · Industrial Applications And Services
EBR Systems, an emerging growth company, announced significant commercial and clinical advancements for Q4 and full-year 2025. The company reported a doubling of WiSE System implant case volumes in Q4, alongside the commencement of two crucial clinical studies: the WiSE-UP post-approval study and the TLC-AU feasibility study. The TLC-AU study is particularly notable as it aims to evaluate totally leadless CRT in de novo patients, which could substantially expand the company's total addressable market. While preliminary revenues remain modest, these operational and clinical milestones indicate strong progress in product adoption and future market expansion, which are critical for an early-stage medical device company.
At the time of this filing, EBRCZ was trading at $0.68 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $319.9M. The 52-week trading range was $0.32 to $1.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.